Sorrento sees promising phase 2 results for abivertinib for lymphoma

wildpixel

• New phase 2a data from China found that Sorrento Therapeutics' (OTCPK:SRNEQ) abivertinib for marginal zone lymphoma achieved an overall response rate (ORR) of ~59%.
• Sorrento (OTCPK:SRNEQ) noted that abivertinib's ORR was higher than AbbVie (ABBV) and Johnson and Johnson's (JNJ) Imbruvica (ibrutinib), with a 46% ORR in the population. Imbruvica is approved for MZL.
• In addition, three of the 27 patients in the trial had a complete response.
• Sorrento (OTCPK:SRNEQ) said it will conduct a phase 3 pivotal trial for abivertinib.

More on Sorrento Therapeutics

• An Update On Sorrento: Hitting Rock Bottom And Finding A Shovel

• A SPAC, Spinoff, And Short Squeeze Walk Into A Bar